Literature DB >> 16775488

Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity.

Nathalie Holmén1, Anna Lundgren, Samuel Lundin, Ann-Marie Bergin, Anna Rudin, Henrik Sjövall, Lena Ohman.   

Abstract

BACKGROUND: Factors determining the extension and degree of inflammation in the colonic mucosa of patients with ulcerative colitis (UC) are largely unknown, but CD4+CD25high regulatory T cells (Tregs) have been implicated to play an important role in suppressing inflammation. Therefore, the aims of this study were to determine whether colonic Tregs have suppressive effects on colonic effector T cells in UC and to analyze the association between segmental colonic Treg distribution and disease activity.
MATERIALS AND METHODS: The suppressive activity of colonic CD4+CD25high Tregs from patients with active UC was determined in coculture assays measuring proliferation and cytokine production. The frequency of Tregs and the expression of the Treg marker FOXP3 were analyzed with flow cytometry and RT-PCR in isolated cells and the whole mucosa from patients with active and inactive disease, as well as healthy mucosa.
RESULTS: Colonic CD4+CD25high T cells from patients with UC suppressed the proliferation and cytokine secretion of colonic effector CD4+ T cells. Healthy controls but not patients with UC had lower Treg frequencies in the sigmoid than in the ascending colon. Patients with UC with active disease had increased frequency of colonic Tregs. The frequency of Tregs was positively correlated with colonic disease activity and serum C-reactive protein.
CONCLUSIONS: Colonic CD4+CD25high Tregs are able to suppress colonic effector T cell activity in vitro, and the Treg frequency in the inflamed intestine increases with disease activity in patients with active UC. This suggests that Tregs may be outnumbered by other inflammatory cells or that their suppressive activity may be influenced by the in vivo environment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775488     DOI: 10.1097/00054725-200606000-00003

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  64 in total

Review 1.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis.

Authors:  Yohei Okada; Noriaki Maeda; Shoji Takakura; Keiji Miyata; Masahiro Koshiba
Journal:  Inflamm Res       Date:  2011-08-10       Impact factor: 4.575

3.  Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease.

Authors:  J Grundström; L Linton; S Thunberg; H Forsslund; I Janczewska; R Befrits; M van Hage; G Gafvelin; M Eberhardson
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 4.  Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations.

Authors:  Jochen Maul; Martin Zeitz
Journal:  Langenbecks Arch Surg       Date:  2011-04-09       Impact factor: 3.445

5.  Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways.

Authors:  Khoa D Nguyen; Claudia Macaubas; Kari C Nadeau; Phi Truong; Taejin Yoon; Tzielan Lee; Jane L Park; Elizabeth D Mellins
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

6.  Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis.

Authors:  Christopher S Smillie; Moshe Biton; Jose Ordovas-Montanes; Keri M Sullivan; Grace Burgin; Daniel B Graham; Rebecca H Herbst; Noga Rogel; Michal Slyper; Julia Waldman; Malika Sud; Elizabeth Andrews; Gabriella Velonias; Adam L Haber; Karthik Jagadeesh; Sanja Vickovic; Junmei Yao; Christine Stevens; Danielle Dionne; Lan T Nguyen; Alexandra-Chloé Villani; Matan Hofree; Elizabeth A Creasey; Hailiang Huang; Orit Rozenblatt-Rosen; John J Garber; Hamed Khalili; A Nicole Desch; Mark J Daly; Ashwin N Ananthakrishnan; Alex K Shalek; Ramnik J Xavier; Aviv Regev
Journal:  Cell       Date:  2019-07-25       Impact factor: 41.582

Review 7.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

8.  Altered generation of induced regulatory T cells in the FVB.mdr1a-/- mouse model of colitis.

Authors:  S M Tanner; E M Staley; R G Lorenz
Journal:  Mucosal Immunol       Date:  2012-08-08       Impact factor: 7.313

9.  Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.

Authors:  Vladislaw Muratov; Ann-Kristin Ulfgren; Marianne Engström; Kerstin Elvin; Ola Winqvist; Robert Löfberg; Joachim Lundahl
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

Review 10.  Regulatory T cells in inflammatory bowel diseases and colorectal cancer.

Authors:  Györgyi Műzes; Béla Molnár; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.